Xtant Medical Holdings, Inc.
XTNTAMEXHealthcare● Active
$0.45
$-0.01(-1.62%)
Market Cap$62907938
P/E Ratio—
52W High$0.95
52W Low$0.44
Xtant Medical Holdings, Inc. (XTNT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
XTNT · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.02
Est. -$0.01 · -33.3%
Revenue
$0.02B
Est. $0.02B · +3.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
XTNT reports quarterly as a AMEX-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.01 | — | — | — | $0.02B | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$0.01 | -$0.02 | -33.3% | $0.02B | $0.02B | +3.6% |
| ▲ Q1 FY2026 | Mar 31, 2026 | -$0.00 | $0.00 | +108.2% | $0.03B | $0.03B | +5.2% |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$0.01 | $0.01 | +290.5% | $0.03B | $0.03B | +8.2% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.01 | $0.02 | +300.0% | $0.04B | $0.03B | +13.5% |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.01 | $0.00 | +104.0% | $0.03B | $0.03B | +5.4% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -$0.01 | -$0.02 | -100.0% | $0.03B | $0.03B | -0.9% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.03 | -$0.04 | -60.0% | $0.03B | $0.03B | -12.1% |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.01
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$0.02
EPS Est.
-$0.01
EPS Surpr.
-33.3%
Revenue
$0.02B
Q1 FY2026
Mar 31, 2026Beat
EPS Actual
$0.00
EPS Est.
-$0.00
EPS Surpr.
+108.2%
Revenue
$0.03B
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
$0.01
EPS Est.
-$0.01
EPS Surpr.
+290.5%
Revenue
$0.03B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
$0.02
EPS Est.
-$0.01
EPS Surpr.
+300.0%
Revenue
$0.04B
Q2 FY2025
May 12, 2025Beat
EPS Actual
$0.00
EPS Est.
-$0.01
EPS Surpr.
+104.0%
Revenue
$0.03B
Q1 FY2025
Mar 6, 2025Miss
EPS Actual
-$0.02
EPS Est.
-$0.01
EPS Surpr.
-100.0%
Revenue
$0.03B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.04
EPS Est.
-$0.03
EPS Surpr.
-60.0%
Revenue
$0.03B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.01 | $0.01 | $0.01 | 1 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 1 |
| Q1 FY2028 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q4 FY2027 | $0.00 | $0.00 | $0.00 | 1 |
| Q3 FY2027 | $-0.01 | $-0.01 | $-0.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -33.3% | $0.50 | $0.48 | -4.84% |
| ▲ Q1 FY2026 | Mar 31, 2026 | +108.2% | $0.54 | $0.56 | +2.76% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +290.5% | $0.75 | $0.76 | +1.12% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +300.0% | $0.59 | $0.67 | +14.08% |
| ▲ Q2 FY2025 | May 12, 2025 | +104.0% | $0.50 | $0.52 | +3.04% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -100.0% | $0.50 | $0.48 | -3.50% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -60.0% | $0.52 | $0.54 | +4.09% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -50.0% | $0.65 | $0.65 | +0.26% |
Q2 FY2026-4.84%
Report Date
May 13, 2026
EPS Beat/Miss
-33.3%
Price Before
$0.50
Price After
$0.48
Q1 FY2026+2.76%
Report Date
Mar 31, 2026
EPS Beat/Miss
+108.2%
Price Before
$0.54
Price After
$0.56
Q4 FY2025+1.12%
Report Date
Nov 10, 2025
EPS Beat/Miss
+290.5%
Price Before
$0.75
Price After
$0.76
Q3 FY2025+14.08%
Report Date
Aug 12, 2025
EPS Beat/Miss
+300.0%
Price Before
$0.59
Price After
$0.67
Q2 FY2025+3.04%
Report Date
May 12, 2025
EPS Beat/Miss
+104.0%
Price Before
$0.50
Price After
$0.52
Q1 FY2025-3.50%
Report Date
Mar 6, 2025
EPS Beat/Miss
-100.0%
Price Before
$0.50
Price After
$0.48
Q4 FY2024+4.09%
Report Date
Nov 12, 2024
EPS Beat/Miss
-60.0%
Price Before
$0.52
Price After
$0.54
Q3 FY2024+0.26%
Report Date
Aug 8, 2024
EPS Beat/Miss
-50.0%
Price Before
$0.65
Price After
$0.65
Avg Beat Reaction+5.25%
Avg Miss Reaction-1.00%
Beat Rate4 / 8 quarters
Largest Move+14.08% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: XTNT ends December
Xtant Medical Holdings, Inc. (XTNT) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.02 — missing the analyst consensus of $-0.01 by -33.3%. The next XTNT earnings date is expected around September 1, 2026.
Each quarter, investors track XTNT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. XTNT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
XTNT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
XTNT earnings · 5 questionsXtant Medical Holdings, Inc.'s next earnings report is expected around September 1, 2026. XTNT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; XTNT historically reports after market close (AMC).
XTNT earnings datewhen is XTNT earningsXTNT next earnings datewhen does XTNT report earningsXTNT earnings calendar
▸ Source: FMP · Xtant Medical Holdings, Inc. SEC filings · US GAAP · Xtant Medical Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026